D.E. Shaw & Co
MRKR icon

D.E. Shaw & Co’s Marker Therapeutics MRKR Stock Holding History

D.E. Shaw & Co’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,212
Closed -$27K – 5400
2022
Q2 		$27K Sell
8,212
-1,609
-16% -$5.35K ﹤0.01% 4955
2022
Q1 		$43K Sell
9,821
-38,518
-80% -$220K ﹤0.01% 5178
2021
Q4 		$459K Buy
48,339
+2,735
+6% +$36.3K ﹤0.01% 4451
2021
Q3 		$771K Sell
45,604
-17,515
-28% -$359K ﹤0.01% 3796
2021
Q2 		$1.76M Buy
63,119
+60,379
+2,204% +$1.59M ﹤0.01% 3072
2021
Q1 		$61K Sell
2,740
-68
-2% -$1.56K ﹤0.01% 3957
2020
Q4 		$41K Buy
+2,808
New +$43.6K ﹤0.01% 3853
2020
Q2 		– Sell
-3,536
Closed -$67K – 4164
2020
Q1 		$67K Buy
3,536
+1,042
+42% +$26.5K ﹤0.01% 3813
2019
Q4 		$72K Buy
+2,494
New +$90.7K ﹤0.01% 3890
2019
Q3 		– Sell
-1,479
Closed -$117K – 3939
2019
Q2 		$117K Buy
+1,479
New +$87.8K ﹤0.01% 3535
2019
Q1 		– Sell
-1,021
Closed -$57K – 3799
2018
Q4 		$57K Buy
+1,021
New +$74.4K ﹤0.01% 3677

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
AAM
AR Asset Management West Hollywood, California $546M AUM 24.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co's MRKR Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Marker Therapeutics (MRKR) in Q3 2022, closing a stake of 8,212 shares — an estimated $27K sold.

D.E. Shaw & Co first reported a position in MRKR in Q4 2018 and held it in 11 quarters. The position peaked at $1.76M in Q2 2021. 45 funds tracked by Wall St. Rank hold MRKR as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Marker Therapeutics position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 8,212 Marker Therapeutics shares in Q3 2022, an estimated $27K.
  • D.E. Shaw & Co first reported a position in Marker Therapeutics in Q4 2018 and held it in 11 quarters.
  • D.E. Shaw & Co's Marker Therapeutics position peaked at $1.76M in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.